Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Research Report 2025(Status and Outlook)

Report Overview

The market for targeted EGFR receptor tyrosine kinase (RTK) inhibitors in non-small cell lung cancer (NSCLC) is a specialized segment of oncology therapeutics focused on precision medicine. These inhibitors, such as gefitinib, erlotinib, afatinib, and osimertinib, selectively block the epidermal growth factor receptor (EGFR), a key driver of tumor proliferation in EGFR-mutant NSCLC. The market has grown significantly due to advancements in biomarker testing and the development of next-generation inhibitors that overcome resistance mutations. Demand is driven by the high prevalence of EGFR mutations in NSCLC, particularly in Asian populations, and the shift toward personalized treatment over conventional chemotherapy. Key players include AstraZeneca, Roche, and Boehringer Ingelheim, with ongoing R&D focused on improving efficacy and addressing acquired resistance. Pricing, reimbursement policies, and competition from immuno-oncology agents like PD-1/PD-L1 inhibitors influence market dynamics. Emerging markets in Asia-Pacific show rapid growth due to increasing diagnosis rates and healthcare investment, while North America and Europe remain dominant in innovation and adoption.

The global Targeted Drug EGFR RTK Inhibitors for NSCLC market size was estimated at USD 6439.0 million in 2024, exhibiting a CAGR of 8.50% during the forecast period.

This report provides a deep insight into the global Targeted Drug EGFR RTK Inhibitors for NSCLC market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Targeted Drug EGFR RTK Inhibitors for NSCLC market in any manner.

Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Beta Pharma

AstraZeneca

Natco Pharma

Qilu Pharmaceutical

Genentech (Roche Group)

Mylan

Teva

OSI Pharmaceuticals

Glenmark Pharmaceuticals

Beacon Pharmaceuticals

Boehringer Ingelheim

Pfizer

ARIAD Pharmaceuticals (Takeda)

Genvio Pharma Limited

Drug International Limted

Everest Pharmaceuticals

Incepta Pharmaceuticals Limited

Cipla Pharma

Dr Reddy's Laboratories

Zydus Cadila

Hetero Drugs

Intas Pharmaceuticals

Alkem Laboratories

RPG Life Sciences

Fresenius Kabi India

Market Segmentation (by Type)

Icotinib

Gefitinib

Erlotinib

Afatinib

Osimertinib

Brigatinib

Others

Market Segmentation (by Application)

Squamous Cell Carcinoma of NSCLC

Adenocarcinoma of NSCLC

Large Cell Carcinoma of NSCLC

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Targeted Drug EGFR RTK Inhibitors for NSCLC Market

Overview of the regional outlook of the Targeted Drug EGFR RTK Inhibitors for NSCLC Market:

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Targeted Drug EGFR RTK Inhibitors for NSCLC Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Targeted Drug EGFR RTK Inhibitors for NSCLC, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

Chapter 13 is the main points and conclusions of the report.

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come


1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Targeted Drug EGFR RTK Inhibitors for NSCLC
1.2 Key Market Segments
1.2.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Segment by Type
1.2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Overview
2.1 Global Market Overview
2.1.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (M USD) Estimates and Forecasts (2020-2033)
2.1.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Sales Estimates and Forecasts (2020-2033)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Competitive Landscape
3.1 Company Assessment Quadrant
3.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Product Life Cycle
3.3 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Sales by Manufacturers (2020-2025)
3.4 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Manufacturers (2020-2025)
3.5 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Average Price by Manufacturers (2020-2025)
3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
3.8 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Competitive Situation and Trends
3.8.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Concentration Rate
3.8.2 Global 5 and 10 Largest Targeted Drug EGFR RTK Inhibitors for NSCLC Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 Targeted Drug EGFR RTK Inhibitors for NSCLC Industry Chain Analysis
4.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Targeted Drug EGFR RTK Inhibitors for NSCLC Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy – April 2025
5.6.3 Global Trade Frictions and Their Impacts to Targeted Drug EGFR RTK Inhibitors for NSCLC Market
5.7 ESG Ratings of Leading Companies
6 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Sales Market Share by Type (2020-2025)
6.3 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Type (2020-2025)
6.4 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Price by Type (2020-2025)
7 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Sales by Application (2020-2025)
7.3 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (M USD) by Application (2020-2025)
7.4 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Sales Growth Rate by Application (2020-2025)
8 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Sales by Region
8.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Sales by Region
8.1.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Sales by Region
8.1.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Sales Market Share by Region
8.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region
8.2.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region
8.2.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Market Share by Region
8.3 North America
8.3.1 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Sales by Country
8.3.2 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Sales by Country
8.4.2 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Sales by Region
8.5.2 Asia Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Targeted Drug EGFR RTK Inhibitors for NSCLC Sales by Country
8.6.2 South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Sales by Region
8.7.2 Middle East and Africa Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Production by Region
9.1 Global Production of Targeted Drug EGFR RTK Inhibitors for NSCLC by Region(2020-2025)
9.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by Region (2020-2025)
9.3 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Production
9.4.1 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Production Growth Rate (2020-2025)
9.4.2 North America Targeted Drug EGFR RTK Inhibitors for NSCLC Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Production
9.5.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Production Growth Rate (2020-2025)
9.5.2 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Production (2020-2025)
9.6.1 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Production Growth Rate (2020-2025)
9.6.2 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Targeted Drug EGFR RTK Inhibitors for NSCLC Production (2020-2025)
9.7.1 China Targeted Drug EGFR RTK Inhibitors for NSCLC Production Growth Rate (2020-2025)
9.7.2 China Targeted Drug EGFR RTK Inhibitors for NSCLC Production, Revenue, Price and Gross Margin (2020-2025)
10 Key Companies Profile
10.1 Beta Pharma
10.1.1 Beta Pharma Basic Information
10.1.2 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
10.1.3 Beta Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
10.1.4 Beta Pharma Business Overview
10.1.5 Beta Pharma SWOT Analysis
10.1.6 Beta Pharma Recent Developments
10.2 AstraZeneca
10.2.1 AstraZeneca Basic Information
10.2.2 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
10.2.3 AstraZeneca Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
10.2.4 AstraZeneca Business Overview
10.2.5 AstraZeneca SWOT Analysis
10.2.6 AstraZeneca Recent Developments
10.3 Natco Pharma
10.3.1 Natco Pharma Basic Information
10.3.2 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
10.3.3 Natco Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
10.3.4 Natco Pharma Business Overview
10.3.5 Natco Pharma SWOT Analysis
10.3.6 Natco Pharma Recent Developments
10.4 Qilu Pharmaceutical
10.4.1 Qilu Pharmaceutical Basic Information
10.4.2 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
10.4.3 Qilu Pharmaceutical Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
10.4.4 Qilu Pharmaceutical Business Overview
10.4.5 Qilu Pharmaceutical Recent Developments
10.5 Genentech (Roche Group)
10.5.1 Genentech (Roche Group) Basic Information
10.5.2 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
10.5.3 Genentech (Roche Group) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
10.5.4 Genentech (Roche Group) Business Overview
10.5.5 Genentech (Roche Group) Recent Developments
10.6 Mylan
10.6.1 Mylan Basic Information
10.6.2 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
10.6.3 Mylan Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
10.6.4 Mylan Business Overview
10.6.5 Mylan Recent Developments
10.7 Teva
10.7.1 Teva Basic Information
10.7.2 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
10.7.3 Teva Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
10.7.4 Teva Business Overview
10.7.5 Teva Recent Developments
10.8 OSI Pharmaceuticals
10.8.1 OSI Pharmaceuticals Basic Information
10.8.2 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
10.8.3 OSI Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
10.8.4 OSI Pharmaceuticals Business Overview
10.8.5 OSI Pharmaceuticals Recent Developments
10.9 Glenmark Pharmaceuticals
10.9.1 Glenmark Pharmaceuticals Basic Information
10.9.2 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
10.9.3 Glenmark Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
10.9.4 Glenmark Pharmaceuticals Business Overview
10.9.5 Glenmark Pharmaceuticals Recent Developments
10.10 Beacon Pharmaceuticals
10.10.1 Beacon Pharmaceuticals Basic Information
10.10.2 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
10.10.3 Beacon Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
10.10.4 Beacon Pharmaceuticals Business Overview
10.10.5 Beacon Pharmaceuticals Recent Developments
10.11 Boehringer Ingelheim
10.11.1 Boehringer Ingelheim Basic Information
10.11.2 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
10.11.3 Boehringer Ingelheim Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
10.11.4 Boehringer Ingelheim Business Overview
10.11.5 Boehringer Ingelheim Recent Developments
10.12 Pfizer
10.12.1 Pfizer Basic Information
10.12.2 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
10.12.3 Pfizer Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
10.12.4 Pfizer Business Overview
10.12.5 Pfizer Recent Developments
10.13 ARIAD Pharmaceuticals (Takeda)
10.13.1 ARIAD Pharmaceuticals (Takeda) Basic Information
10.13.2 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
10.13.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
10.13.4 ARIAD Pharmaceuticals (Takeda) Business Overview
10.13.5 ARIAD Pharmaceuticals (Takeda) Recent Developments
10.14 Genvio Pharma Limited
10.14.1 Genvio Pharma Limited Basic Information
10.14.2 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
10.14.3 Genvio Pharma Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
10.14.4 Genvio Pharma Limited Business Overview
10.14.5 Genvio Pharma Limited Recent Developments
10.15 Drug International Limted
10.15.1 Drug International Limted Basic Information
10.15.2 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
10.15.3 Drug International Limted Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
10.15.4 Drug International Limted Business Overview
10.15.5 Drug International Limted Recent Developments
10.16 Everest Pharmaceuticals
10.16.1 Everest Pharmaceuticals Basic Information
10.16.2 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
10.16.3 Everest Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
10.16.4 Everest Pharmaceuticals Business Overview
10.16.5 Everest Pharmaceuticals Recent Developments
10.17 Incepta Pharmaceuticals Limited
10.17.1 Incepta Pharmaceuticals Limited Basic Information
10.17.2 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
10.17.3 Incepta Pharmaceuticals Limited Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
10.17.4 Incepta Pharmaceuticals Limited Business Overview
10.17.5 Incepta Pharmaceuticals Limited Recent Developments
10.18 Cipla Pharma
10.18.1 Cipla Pharma Basic Information
10.18.2 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
10.18.3 Cipla Pharma Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
10.18.4 Cipla Pharma Business Overview
10.18.5 Cipla Pharma Recent Developments
10.19 Dr Reddy's Laboratories
10.19.1 Dr Reddy's Laboratories Basic Information
10.19.2 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
10.19.3 Dr Reddy's Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
10.19.4 Dr Reddy's Laboratories Business Overview
10.19.5 Dr Reddy's Laboratories Recent Developments
10.20 Zydus Cadila
10.20.1 Zydus Cadila Basic Information
10.20.2 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
10.20.3 Zydus Cadila Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
10.20.4 Zydus Cadila Business Overview
10.20.5 Zydus Cadila Recent Developments
10.21 Hetero Drugs
10.21.1 Hetero Drugs Basic Information
10.21.2 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
10.21.3 Hetero Drugs Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
10.21.4 Hetero Drugs Business Overview
10.21.5 Hetero Drugs Recent Developments
10.22 Intas Pharmaceuticals
10.22.1 Intas Pharmaceuticals Basic Information
10.22.2 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
10.22.3 Intas Pharmaceuticals Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
10.22.4 Intas Pharmaceuticals Business Overview
10.22.5 Intas Pharmaceuticals Recent Developments
10.23 Alkem Laboratories
10.23.1 Alkem Laboratories Basic Information
10.23.2 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
10.23.3 Alkem Laboratories Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
10.23.4 Alkem Laboratories Business Overview
10.23.5 Alkem Laboratories Recent Developments
10.24 RPG Life Sciences
10.24.1 RPG Life Sciences Basic Information
10.24.2 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
10.24.3 RPG Life Sciences Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
10.24.4 RPG Life Sciences Business Overview
10.24.5 RPG Life Sciences Recent Developments
10.25 Fresenius Kabi India
10.25.1 Fresenius Kabi India Basic Information
10.25.2 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Product Overview
10.25.3 Fresenius Kabi India Targeted Drug EGFR RTK Inhibitors for NSCLC Product Market Performance
10.25.4 Fresenius Kabi India Business Overview
10.25.5 Fresenius Kabi India Recent Developments
11 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast by Region
11.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast
11.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Country
11.2.3 Asia Pacific Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Region
11.2.4 South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Targeted Drug EGFR RTK Inhibitors for NSCLC by Country
12 Forecast Market by Type and by Application (2026-2033)
12.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast by Type (2026-2033)
12.1.1 Global Forecasted Sales of Targeted Drug EGFR RTK Inhibitors for NSCLC by Type (2026-2033)
12.1.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Forecast by Type (2026-2033)
12.1.3 Global Forecasted Price of Targeted Drug EGFR RTK Inhibitors for NSCLC by Type (2026-2033)
12.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Forecast by Application (2026-2033)
12.2.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Sales (K Units) Forecast by Application
12.2.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (M USD) Forecast by Application (2026-2033)
13 Conclusion and Key Findings

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings